Generalized tetanus in a patient with a diabetic foot infection

Pharmacotherapy

Volumn 19, Issue 7, 1999, Pages 885-890

  Panning, Chad A ^a   Bayat, Maryam ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; DOPAMINE; DOXYCYCLINE; FENTANYL; HUMAN IMMUNOGLOBULIN; LEVOFLOXACIN; LORAZEPAM; METRONIDAZOLE; PANCURONIUM; PENICILLIN DERIVATIVE; SULTAMICILLIN; TETANUS ANTIBODY; TETANUS TOXOID;

ADULT; ARTICLE; CASE REPORT; CLOSTRIDIUM TETANI; DIABETIC FOOT; HUMAN; HYPERTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; MUSCLE SPASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; TETANUS; WOUND CARE; WOUND INFECTION;

BACTERIAL INFECTIONS; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; ENTEROCOCCUS; HUMANS; MALE; MIDDLE AGED; PROTEUS; STAPHYLOCOCCUS AUREUS; TETANUS;

EID: 0032878733     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.10.885.31549     Document Type: Article

References (22)

1. Popoff MR. Ecology of neurotoxigenic strains of clostridia. Curr Top Microbiol Immunol 1995;195:1-29.
2. Bleck TP. Pharmacology of tetanus. Clin Neuropharmacol 1986;9(2):103-20.
3. Bleck TP. Tetanus: pathophysiology, management, and prophylaxis. Dis Month 1991;37(9):545-603.
4. Groleau G. Tetanus. Emerg Med Clin North Am 1992;10(2): 351-60.
5. Ernst ME, Klepser ME, Fouts M, Marangos MN. Tetanus: pathophysiology and management. Ann Pharmacother 1997;31:1507-13.
6. Richardson JP, Knight AL. The management and prevention of tetanus. J Emerg Med 1993;11(6):737-42.
7. Centers for Disease Control. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991; 40(RR-10):1-28.
8. Bardenheier B, Prevots DR, Khetsurianai N, Wharton M. Tetanus surveillance - United States, 1995-1997. MMWR 1998;47(2):1-13.
9. Centers for Disease Control. Notice to readers recommended childhood immunization schedule - United States, 1999. MMWR 1999;48(1):8-16.
10. Blake PA, Feldman RA, Buchanan TM, Brooks GF, Bennett JV. Serologic therapy of tetanus in the United States. JAMA 1976;235:42-4.
11. Kefer MP. Tetanus. Am J Emerg Med 1992;10(5):445-8.
12. Neequaye J, Nkrumah FK. Failure of intrathecal anti-tetanus serum to improve survival in neonatal tetanus. Arch Dis Child 1983;58:276-8.
13. Begue RE, Lindo-Soriano I. Failure of intrathecal tetanus antitoxin in the treatment of tetanus neonatorium. J Infect Dis 1991;164;419-20.
14. Gupta PS, Goyal S, Kapoor R, Bata VK, Jain BK. Intrathecal human tetanus immunoglobulin in early tetanus. Lancet 1980;2:439-40.
15. Shann F. Intrathecal administration of tetanus antiserum. Med J Aust 1983;2:604-5.
16. Lee DC, Lederman HM. Anti-tetanus toxoid antibodies in intravenous gamma globulin: an alternative to tetanus immune globulin. J Infect Dis 1993;167(2):498-9.
17. Stair TO, Lippe MA, Russell H, Feeley JC. Tetanus immunity in emergency department patients. Am J Emerg Med 1989;7:563-6.
18. Levine L, Edsall G. Tetanus toxoid: what determines reaction proneness? J Infect Dis 1981;144(4):376.
19. Ahmadsyah I, Salim A. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. Br Med J 1985;291(6496):648-50.
20. Middlebrook JL, Brown JE. Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins. Curr Top Microbiol Immunol 1995;195:89-122.
21. Sloane P, Rizzolo P, Citron D, et al. Implementation of recommended health maintenance activities in geriatric care. Fam Med 1985;17(4):140-3.
22. Vondracek TG, Pham TP, Huycke MM. A hospital-based pharmacy intervention program for pneumococcal vaccination. Arch Intern Med 1998;158:1543-7.